Riskpilot← Back to searchSign inGet full accessCosmodemian AB
ABActiveOrg 5569315905Granelidsvägen 17 AMedical specialists activities · NACE 8622Est. 20132 employees
Revenue 2025
SEK 5,7M
0% vs 2024
EBITDA margin
49.8%
-15% vs 2024
Equity ratio
29.5%
Financial strength
Net profit 2025
SEK 2M
-7% vs 2024
| Revenue | SEK 5,7M | +0% |
| EBITDA | SEK 2,9M | -15% |
| Net profit | SEK 2M | -7% |
| Total assets | SEK 7,3M | +1% |
| Equity | SEK 2,1M | -4% |
| Employees | 2 | — |
Legal name
Cosmodemian AB
Org number
5569315905
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
13 maj 2013
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanterna
Company purpose
Företaget ska bedriva medicinsk vård och forskning inom primärt området allmänkirurgi och gynekologi.
Address
Granelidsvägen 17 A
Email
peterakerud@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 5 248 | 5 359 | 5 522 | 5 695 | 5 722 |
| Staff expenses | — | −1 394 | −1 456 | −1 419 | −1 887 |
| EBITDA | 3 860 | 3 166 | 2 949 | 3 355 | 2 852 |
| Depreciation & amort. | −673 | −441 | −172 | −154 | −137 |
| EBIT | 3 187 | 2 725 | 2 777 | 3 200 | 2 716 |
| Net financials | −18 | −95 | 168 | 79 | 23 |
| Profit before tax | 2 132 | 1 978 | 2 684 | 2 745 | 2 559 |
| Tax | −447 | −437 | −558 | −594 | −554 |
| Net profit | 1 685 | 1 541 | 2 127 | 2 152 | 2 006 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 5 554 | 6 255 | 6 941 | 7 161 | 7 261 |
| Equity | 1 816 | 1 657 | 2 183 | 2 235 | 2 140 |
| Long-term debt | 0 | — | — | — | 13 |
| Short-term debt | 237 | 868 | 767 | 403 | 418 |
| Total debt | 237 | 868 | 767 | 403 | 431 |
EBITDA margin
49.8%
This company
15.8%
Market median
+215% vs market
20212025
Equity ratio
29.5%
This company
38.2%
Market median
-23% vs market
20212025
Return on equity
93.7%
This company
18.4%
Market median
+409% vs market
20212025
Net profit margin
35.0%
This company
8.1%
Market median
+332% vs market
20212025
Asset turnover
0.79×
This company
1.12×
Market median
-29% vs market
20212025
Debt / equity
2.39×
This company
0.62×
Market median
-285% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AM Audit | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2025 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Åkerud Medical Consulting AB
Cosmodemian AB Board members of Cosmodemian AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anne Marie Svedare | Audit | 0 companies |
| Jan Peter Mikael Åkerud | Board of Directors | 0 companies |
| Axel Sigurd Verner Åkerud | Deputy Board Member | 0 companies |
| Åsa Helena Åkerud Larsson | Deputy Board Member | 0 companies |